Table 1.xls (5.5 kB)

Baseline characteristics and corresponding primary efficacy outcomes of the Phase 3 trials included.

Name: Baseline characteristics and corresponding primary efficacy outcomes of the Phase 3 trials included.
Published: 2018-05-24T18:04:06+00:00
License: https://creativecommons.org/licenses/by/4.0/
Keywords: trial participants, Few meta-analyses, venous thromboembolism, GIB, NVAF, Conclusions Patients, Systematic review, VTE randomized, DOAC recipients, DVT, PE, FDA-approved DOAC, non-inferior efficacy, non-valvular atrial fibrillation, vitamin K antagonists, meta-analysis Background, Phase 3 randomized trials, CI, Pooled Odds Ratio, FDA approval, safety profile, VKA

dataset

posted on 2018-05-24, 18:04 authored by Raghavendra Charan P. Makam, David C. Hoaglin, David D. McManus, Victoria Wang, Joel M. Gore, Frederick A. Spencer, Richeek Pradhan, Hoang Tran, Hong Yu, Robert J. Goldberg

Baseline characteristics and corresponding primary efficacy outcomes of the Phase 3 trials included.

History

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports